Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
108.50
+2.00 (1.88%)
Real-time:   11:14AM GMT+2
CPH real-time data - Disclaimer
Currency in DKK
Range 107.00 - 109.00
52 week 54.50 - 110.00
Open 107.00
Vol / Avg. 55,986.00/119,045.00
Mkt cap 2.83B
P/E     -
Div/yield     -
EPS -1.79
Shares 26.09M
Beta     -
Inst. own     -
Jun 1, 2014
Bavarian Nordic A/S PROSTVAC Update and Reception - 12:00AM GMT+2 - Add to calendar
May 14, 2014
Q1 2014 Bavarian Nordic A/S Earnings Release Add to calendar
Apr 24, 2014
Bavarian Nordic A/S Annual General Meeting - 5:00PM GMT+2 - Add to calendar
Mar 19, 2014
Full Year 2013 Bavarian Nordic A/S Earnings Conference Call - Webcast
Mar 19, 2014
Full Year 2013 Bavarian Nordic A/S Earnings Release
Mar 11, 2014
Bavarian Nordic A/S at EBD BIO-Europe Spring
Mar 4, 2014
Bavarian Nordic A/S at Credit Suisse Healthcare Conference
Feb 10, 2014
Bavarian Nordic A/S at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -7.95% -3.85%
Operating margin 11.68% 2.76%
EBITD margin - 6.37%
Return on average assets -7.40% -3.12%
Return on average equity -10.91% -4.73%
Employees 426 -
CDP Score - -

Address

Hejreskovvej 10A
KVISTGAARD, 3490
Denmark

Website links

Description

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines� pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC and MVA-BN PRO; two projects in breast cancer, CV-301 and MVA-BN HER2; one project in lung cancer, CV-301 lung, and one project in ovarian cancer, CV-301 ovarian. The Infectious Disease�s pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate; an anthrax vaccine candidate, MVA-BN Anthrax, and a RSV vaccine candidate, MVA-BN RSV. Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany.

Officers and directors

Asger Aamund Chairman of the Board
Age: 73
Anders Hedegaard Chief Executive Officer, President
Age: 53
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 48
James B. Breitmeyer Executive Vice President, Division President of Cancer Vaccine
Paul Chaplin Executive Vice President, Division President Infectious Diseases
Age: 46
Peter Kurstein Director
Age: 57
Claus Braestrup Ph.D. Independent Director
Age: 69
Erik Gregers Hansen Independent Director
Age: 61
Anders Gersel Pedersen Independent Director
Age: 62
Gerard W. M. van Odijk Independent Director
Age: 57